11 citations
,
January 1995 in “Biomedicine & pharmacotherapy” TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
64 citations
,
January 2001 in “Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy” Misoprostol has many medical benefits, including protecting against injuries, aiding in disease treatment, and improving drug effects.
September 2004 in “Urology” Finasteride may reduce prostate cancer risk.
20 citations
,
January 2003 in “Dermatology online journal” Prostaglandin analogs like Latanoprost might help grow hair on the scalp and body.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
1 citations
,
March 2023 in “Frontiers in Medicine” Topical prostaglandin analogs may help with hair growth but more research is needed.
January 2006 in “Zhongguo yaofang” The market for these drugs is expected to grow.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference”
14 citations
,
January 2020 in “Biomaterials Science” Created microspheres show potential for safe and effective use in prostate artery embolization.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
December 2023 in “Journal of ethnopharmacology” Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
5 citations
,
January 1991 in “Drugs of The Future” 408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
33 citations
,
July 2009 in “Therapeutics and Clinical Risk Management” Finasteride effectively reduces prostate size and lowers surgery risk in men with benign prostatic hyperplasia.
January 2013 in “Zhonghua linchuang yishi zazhi” Taking finasteride for over a month before surgery reduces blood loss during TURP.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
May 2024 in “Scientific African” Three natural compounds from Ghanaian plants may help treat BPH and alopecia.
February 2023 in “Reactions Weekly” March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
104 citations
,
January 2005 in “Climacteric” Drospirenone is a unique progestin with anti-water retention and potential blood pressure benefits, used in birth control and hormone therapy.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
December 2022 in “Dermatologie pro praxi” Combining PRP, minoxidil, and finasteride significantly improved hair regrowth.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
January 2019 in “11th World congress for hair research”
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
March 2020 in “StatPearls” Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.
8 citations
,
March 2005 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Bimatoprost eye drops can cause temporary eyelid changes and may help with hair growth research.
8 citations
,
February 2019 in “Journal of The European Academy of Dermatology and Venereology”